Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AMG 162

Known as: 162, AMG, AMG-162 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Introduction: Denosumab, a fully human monoclonal antibody, targets the receptor activator of nuclear factor-kappaB (RANK) ligand… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Review
2009
Review
2009
Objective: To review the pharmacology, pharmacokinetics, pharmacodynamics, safety, efficacy, and use of denosumab in osteoporosis… Expand
  • figure 1
2008
2008
  • E. Lewiecki
  • Biologics : targets & therapy
  • 2008
  • Corpus ID: 16510807
Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor… Expand
Review
2006
Review
2006
Purpose of reviewInflammation-induced osteolysis is a problem in both inflammatory arthritis and total joint arthroplasty. New… Expand
Review
2005
Review
2005
Bone health is an increasingly important concern in breast cancer survivors because in postmenopausal women, bone-sparing… Expand
2005
2005
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
2005
2005
Oncologists have always been dedicated to fully understanding the toxicities associated with the cancer treatments they… Expand
Review
2005
Review
2005
RANKL is an essential factor for osteoclastogenesis. Amgen research group has developed AMG 162, a fully human monoclonal… Expand
Highly Cited
2004
Highly Cited
2004
The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was… Expand
2004
2004
8106 Background: RANKL is an essential osteoclastic differentiation/activation factor. AMG 162 PK and PD were evaluated in a… Expand